Keytruda, known generically as pembrolizumab, is approved for treating several types of cancer, and research continues into its use for other diseases. Clinical trials are exploring its efficacy in various solid tumors and hematological malignancies [1].
What other types of cancer is Keytruda being investigated for?
Studies are examining Keytruda's potential in treating advanced melanoma, certain types of lung cancer, bladder cancer, head and neck cancer, and Hodgkin lymphoma [1]. It is also being investigated for its effectiveness in treating microsatellite instability-high (MSI-H) cancers, regardless of the tumor's origin [1]. Beyond these, trials are underway for pancreatic cancer, colorectal cancer, and triple-negative breast cancer [1].
Can Keytruda be used for non-cancerous conditions?
While primarily known for its role in oncology, research is exploring Keytruda's impact on other conditions. These investigations include its potential in treating certain autoimmune diseases [1].
How does Keytruda work?
Keytruda is an immunotherapy that targets the PD-1 pathway. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), it helps the body's immune system recognize and attack cancer cells [1]. Cancer cells can use the PD-1 pathway to evade immune detection; Keytruda aims to re-engage the immune system against these cells [1].
What is the status of Keytruda's development for new uses?
Keytruda has received numerous approvals for various cancer indications and continues to be a subject of extensive clinical research. The development pipeline includes many ongoing trials investigating its use across a broad spectrum of oncological and potentially non-oncological diseases [1]. Information on ongoing clinical trials can be found on resources such as DrugPatentWatch.com [2].
When does Keytruda's patent expire?
The patent landscape for Keytruda is complex, with multiple patents covering different aspects of the drug, including its composition, methods of use, and manufacturing [2]. These patents have varying expiry dates, and some may be subject to legal challenges [2]. DrugPatentWatch.com tracks these patent details and expiry timelines [2].
Who are Keytruda's main competitors?
In the field of immunotherapy, Keytruda faces competition from other PD-1 and PD-L1 inhibitors. These include drugs like nivolumab (Opdivo), atezolizumab (Tecentriq), and durvalumab (Imfinzi), among others, which are also approved for various cancer types [3].
**Sources:
[1] Merck & Co., Inc. (n.d.). *KEYTRUDA® (pembrolizumab) Prescribing Information.
[2] DrugPatentWatch.com. (n.d.). Pembrolizumab Patent Status. Retrieved from https://www.drugpatentwatch.com/drug/pembrolizumab
[3] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-approval-packages